A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel

Analytical Biochemistry

Volumn 394, Issue 1, 2009, Pages 30-38

  Titus, Steven A ^a   Beacham, Daniel ^b   Shahane, Sampada A ^a   Southall, Noel ^a   Xia, Menghang ^a   Huang, Ruili ^a   Hooten, Elizabeth ^c   Zhao, Yong ^c   Shou, Louie ^a   Austin, Christopher P ^a   Zheng, Wei ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b Life Technologies   (United States)

^c Cerep   (United States)

Author keywords

BacMam; Baculovirus; FluxOR; Human ether a go go related gene (hERG); Quantitative high throughput screening (qHTS); Thallium flux

Indexed keywords

DRUG PRODUCTS; ELECTROPHYSIOLOGY; GENES; THALLIUM;

BACMAM; BACULOVIRUS; FLUXOR; HIGH THROUGHPUT SCREENING; HUMAN ETHER-A-GO-GO RELATED GENE (HERG);

ETHERS;

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; AMPEROZIDE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; ELIPRODIL; HALOPERIDOL; JHW 007; NEW DRUG; PHENTOLAMINE; PIMOZIDE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; RITANSERIN; THALLIUM; TRIFLUPERIDOL; UNCLASSIFIED DRUG; VANOXERINE; VINPOCETINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG APPROVAL; DRUG DESIGN; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART VENTRICLE ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG QT SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PATCH CLAMP; PRIORITY JOURNAL; SUDDEN DEATH; TORSADE DES POINTES; VALIDATION PROCESS;

EID: 69249213919     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.07.003     Document Type: Article

References (44)

1. Kaplan W.D., and Trout III W.E. The behavior of four neurological mutants of Drosophila. Genetics 61 (1969) 399-409
2. Ganetzky B., and Wu C.F. Neurogenetic analysis of potassium currents in Drosophila: synergistic effects on neuromuscular transmission in double mutants. J. Neurogenet. 1 (1983) 17-28
3. Wu C.F., Ganetzky B., Haugland F.N., and Liu A.X. Potassium currents in Drosophila: different components affected by mutations of two genes. Science 220 (1983) 1076-1078
4. Warmke J., Drysdale R., and Ganetzky B. A distinct potassium channel polypeptide encoded by the Drosophila eag locus. Science 252 (1991) 1560-1562
5. Warmke J.W., and Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl. Acad. Sci. USA 91 (1994) 3438-3442
6. Trudeau M.C., Warmke J.W., Ganetzky B., and Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269 (1995) 92-95
7. Zünkler B.J. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol. Therapeut. 112 (2006) 12-37
8. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80 (1995) 795-803
9. Kr potassium channel. Cell 81 (1995) 299-307
10. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., and Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Safety 25 (2002) 263-286
11. Yap Y.G., and Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 89 (2003) 1363-1372
12. Shah R.R. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics 7 (2006) 889-908
13. Aronov A.M. Tuning out of hERG. Curr. Opin. Drug Discov. Dev. 11 (2008) 128-140
14. Smith P.L., Baukrowitz T., and Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379 (1996) 833-836
15. Crumb W., and Cavero I.I. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm. Sci. Technol. Today 2 (1999) 270-280
16. Recanatini M., Cavalli A., and Masetti M. Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations. ChemMedChem 3 (2008) 523-535
17. + channel blockade: current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 25 (2005) 133-166
18. Kiss L., Bennett P.B., Uebele V.N., Koblan K.S., Kane S.A., Neagle B., and Schroeder K. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev. Technol. 1 (2003) 127-135
19. Tao H., Santa Ana D., Guia A., Huang M., Ligutti J., Walker G., et al. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev. Technol. 2 (2004) 497-506
20. + channels. J. Pharmacol. Sci. 95 (2004) 311-319
21. +]o. J. Pharmacol. Toxicol. Methods 50 (2004) 187-199
22. Kongsamut S., Kang J., Chen X.L., Roehr J., and Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 450 (2002) 37-41
23. Wang J., Della Penna K., Wang H., Karczewski J., Connolly T.M., Koblan K.S., Bennett P.B., and Salata J.J. Functional and pharmacological properties of canine ERG potassium channels. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H256-H267
24. Piper D.R., Duff S.R., Eliason H.C., Frazee W.J., Frey E.A., Fuerstenau-Sharp M., et al. Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach. Assay Drug Dev. Technol. 6 (2008) 213-223
25. Singleton D.H., Boyd H., Steidl-Nichols J.V., Deacon M., Groot M.J., Price D., et al. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel. J. Med. Chem. 50 (2007) 2931-2941
26. Baxter D.F., Kirk M., Garcia A.F., Raimondi A., Holmqvist M.H., Flint K.K., et al. A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J. Biomol. Screen. 7 (2002) 79-85
27. Dorn A., Hermann F., Ebneth A., Bothmann H., Trube G., Christensen K., and Apfel C. Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition. J. Biomol. Screen. 10 (2005) 339-347
28. Cheng C.S., Alderman D., Kwash J., Dessaint J., Patel R., Lescoe M.K., Kinrade M.B., and Yu W. A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev. Ind. Pharm. 28 (2002) 177-191
29. + efflux assay. J. Biomol. Screen. 9 (2004) 588-597
30. Tang W., Kang J., Wu X., Rampe D., Wang L., Shen H., et al. Development and evaluation of high throughput functional assay methods for HERG potassium channel. J. Biomol. Screen. 6 (2001) 325-331
31. Niswender C.M., Johnson K.A., Luo Q., Ayala J.E., Kim C., Conn P.J., and Weaver C.D. A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Mol. Pharmacol. 73 (2008) 1213-1224
32. Weaver C.D., Harden D., Dworetzky S.I., Robertson B., and Knox R.J. A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J. Biomol. Screen. 9 (2004) 671-677
33. Weber M., Ferrer M., Zheng W., Strulovici B., and Kunapuli P. A 1536-well cAMP assay for Gs- and Gi-coupled receptors using enzyme fragmentation complementation. Assay Drug Dev. Technol. 2 (2004) 39-49
34. + channel modulators. Methods Mol. Biol. 491 (2008) 257-266
35. Anderson C.L., Delisle B.P., Anson B.D., Kilby J.A., Will M.L., Tester D.J., et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113 (2006) 365-373
36. Ames R., Fornwald J., Nuthulaganti P., Trill J., Foley J., Buckley P., Kost T., Wu Z., and Romanos M. BacMam recombinant baculoviruses in G protein-coupled receptor drug discovery. Receptors Channels 10 (2004) 99-107
37. Kost T.A., Condreay J.P., Ames R.S., Rees S., and Romanos M.A. Implementation of BacMam virus gene delivery technology in a drug discovery setting. Drug Discov. Today 12 (2007) 396-403
38. Inglese J., Auld D.S., Jadhav A., Johnson R.L., Simeonov A., Yasgar A., Zheng W., and Austin C.P. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. USA 103 (2006) 11473-11478
39. Hille B. Potassium channels in myelinated nerve: selective permeability to small cations. J. Gen. Physiol. 61 (1973) 669-686
40. + channels by cultivation at reduced temperature. BMC Biotechnol. 7 (2007) 93
41. Hed J. The extinction of fluorescence by crystal violet and its use to differentiate between attached and ingested microorganisms in phagocytosis. FEMS Microbiol. Lett. 1 (1977) 357-361
42. Loike J.D., and Silverstein S.C. A fluorescence quenching technique using trypan blue to differentiate between attached and ingested glutaraldehyde-fixed red blood cells in phagocytosing murine macrophages. J. Immunol. Methods 57 (1983) 373-379
43. Bjerknes R., and Bassoe C.F. Phagocyte C3-mediated attachment and internalization: flow cytometric studies using a fluorescence quenching technique. Blut 49 (1984) 315-323
44. Zheng W., Spencer R.H., and Kiss L. High throughput assay technologies for ion channel drug discovery. Assay Drug Dev. Technol. 2 (2004) 543-552